NCT00364273View on ClinicalTrials.gov

GSK159802 In Healthy Male Subjects And Asthmatics

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 24, 2005

Primary Completion Date

July 6, 2006

Study Completion Date

July 6, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK159802

GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.

DRUG

Placebo

Subjects will receive placebo administered using DISKUS inhaler.

DRUG

Salmeterol

Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.

Trial Locations (2)

M23 9LT

GSK Investigational Site, Manchester

Unknown

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY